505(b)(2) Pathway Fill Important Role in Generic's Future
...a panel discussion was held with CEOs of top generic pharmaceutical companies and key financial analysts.
At last week's Generic Pharmaceutical Association (GPhA) annual meeting held in Orlando, a panel discussion was held with CEOs of top generic pharmaceutical companies and key financial analysts. Much of the discussion focused on the financial ramifications of fewer and lower-value small-molecule drugs coming off patent and being available for generic development. The consensus among the CEOs present seemed to be that 505(b)(2) products would fill an important role in their financial future. All of the CEO’s indicated a willingness to explore in-licensing where warranted.
Read the full release here.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
